NephroPlus Q1FY27 Revenue Jumps 23.7% YoY to ₹281.8 Crore, Adj. EBITDA Up 30.7%
NephroPlus reported Q1FY27 revenue of ₹281.8 crore, up 23.7% YoY. Adjusted EBITDA increased 30.7% YoY to ₹65.1 crore, and Adjusted PAT grew 41.7% YoY to ₹36.8 crore. Treatments rose 13.3% to 10.31 lakh. The company expanded its network to 550 clinics across 5 countries.
The announcement details significant financial growth and strategic expansion, which are material events for investors and indicate strong operational performance and future potential.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with an expanding network and positive commentary from management regarding future growth prospects and market position.
Nephrocare Health Services Limited (NephroPlus) announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The company reported a revenue of ₹281.8 crore for Q1FY27, marking a significant 23.7% year-on-year increase. This growth was driven by a 13.3% rise in treatments to 10.31 lakh and a 9.2% improvement in revenue per treatment to ₹2,733.
Adjusted EBITDA for the quarter stood at ₹65.1 crore, a 30.7% increase year-on-year, with the adjusted EBITDA margin expanding by 120 basis points to 23.1%. Adjusted Profit After Tax (PAT) grew by 41.7% year-on-year to ₹36.8 crore. The company's network expanded to 550 operating clinics across 5 countries, including a milestone of 50 clinics in the Philippines.
Mr. Vikram Vuppala, Chairman & MD, highlighted the shift in the dialysis market from unorganized to organized sectors, positioning NephroPlus to benefit as the market leader. He also mentioned plans to explore new countries through strategic acquisitions or partnerships.
Mr. Rohit Singh, Group Chief Executive Officer, noted the strong financial performance and strategic expansion, emphasizing the launch of the NephroPlus International Dialysis Academy (NIDA) to address the global shortage of renal nurses. Initiatives to improve clinical outcomes, such as the NephroPlus Dialysis Index, were also highlighted.
Mr. Prashant Goenka, Chief Financial Officer, commented on the strength of the India platform and the company's disciplined capital deployment, which is expected to drive durable, long-term value creation.
What to do with a filing like this
Nephrocare Health Services Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nephrocare Health Services Limited. Read the original for the full detail.